Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
10.3346/jkms.1995.10.5.314
- Author:
Yang Ree KIM
1
;
Jin Hong YOO
;
Jae Kyun HUR
;
Jin Han KANG
;
Wan Shik SHIN
;
Moon Won KANG
Author Information
1. Department of Internal Medicine, Catholic University Medical College, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Vi CPS vaccine;
Typhoid fever;
Immunogenicity
- MeSH:
Adolescent;
Adult;
Antibodies, Bacterial/blood;
Antigens, Bacterial/immunology;
Child;
Evaluation Studies;
Human;
Polysaccharides, Bacterial/*immunology;
Salmonella typhi/*immunology;
Typhoid Fever/prevention & control;
Typhoid-Paratyphoid Vaccines/adverse effects/immunology/*therapeutic use
- From:Journal of Korean Medical Science
1995;10(5):314-317
- CountryRepublic of Korea
- Language:English
-
Abstract:
The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.
